非小细胞肺癌：EGFR基因突变：经典突变：靶向治疗：汇总🔢

EGFR基因突变：经典突变	方案	ORR(95% CI)	PFS/DFS,月(95% CI)	PFS,HR(95% CI)	OS,月(95%CI)	OS,HR(95% CI)
EURTAC	Erlotinib vs 化疗	58% (NR)	9·7 (8·4–12·3)	0·37 (0·25–0·54)	19·3 (14·7–26·8)	1·04 (0·65–1·68, p=0·87)
IPASS (EGFR subgroup)	Gefitinib vs 化疗	71% (NR)	NA	0·48 (0·36–0·64)	21·6 (NR)	1·00 (0·76–1·33, p=0·99)
LUX lung 3	Afatinib vs 化疗	56% (NR)	11·1 (NR)	0·58 (0·43–0·78)	28·2 (24·6–33·6)*	0·88 (0·66–1·17, p=0·39)
ARCHER1050	Dacomitinib vs Gefitinib	75% (60–87)	14·7 (11·1–16·6)	0·59 (0·47–0·74)	34·1 (29·5–37·7)	0·74 (0·59–0·94)
FLAURA	Osimertinib vs 厄洛替尼/吉非替尼	80% (75–85)	18·9 (15·2- 21·4)	0·46 (0·3–0·57)	38·6 (34·5–41·8)	0·80 (0·64–1·00)
FLAURA2	Osimertinib plus 化疗 vs Osimertinib	NR	29·4 (25·1–NE)	0·62 (0·48–0·80)	NE	NE
MARIPOSA	Amivantamab plus lazertinib vsOsimertinib	86% (83–89)	23·7 (19·1–27·7)	0·70 (0·58–0·85)	NE	0·80 (0·61–1·05, p=0·11)†

EGFR Thr790Met mutations, 晚期	Agent	ORR(95% CI)	PFS/DFS,月(95% CI)	PFS,HR(95% CI)	OS,月(95%CI)	OS,HR(95% CI)
AURA3	Osimertinib (second-line) vs化疗	71% (65–76)	10·1 (NR)	0·3 (0·23–0·41)	26·8 (23·5–31·5)	0·87 (0·67–1·12, p=0·277)

Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024 Aug 24;404(10454):803-822. doi: 10.1016/S0140-6736(24)01029-8. Epub 2024 Aug 6. PMID: 39121882.